Could a diabetes pill protect your heart valve?

NCT ID NCT05143177

Terminated Disease control Sponsor: REDNVIA Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Apr 04, 2026 · Last updated Jun 22, 2026 · Updated 15 times

Summary

This study tests whether evogliptin, a drug originally for diabetes, can slow calcium buildup in the aortic valve of people with mild to moderate aortic stenosis. About 580 adults will take either the drug or a placebo daily for two years. The main goal is to see if the drug reduces valve calcification on CT scans.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Aurora Research Institute

Milwaukee, Wisconsin, 53215, United States
Baycare Health systems

Safety Harbor, Florida, 34695, United States
Beaumont Hospital, Royal Oak

Royal Oak, Michigan, 48073, United States
Christ Hospital

Cincinnati, Ohio, 45219, United States
Einstein Medical Center Philadelphia

Philadelphia, Pennsylvania, 19141, United States
Hackensack Meridian Health

Hackensack, New Jersey, 07601, United States
Henry Ford Health System

Detroit, Michigan, 48202, United States
Ichan School of Medicine

New York, New York, 10025, United States
Inova Health Care Services

Falls Church, Virginia, 22042, United States
Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval

Québec, Canada
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Mayo Clinic, AZ

Phoenix, Arizona, 85054, United States
Mayo Clinic, FL

Jacksonville, Florida, 32224, United States
Northside Hospital

Atlanta, Georgia, 30342, United States
OhioHealth Research Institute

Columbus, Ohio, 43214, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
Rutgers- Robert Wood Johnson Medical School

New Brunswick, New Jersey, 08901, United States
Stony brook

Stony Brook, New York, 11974, United States
Texas Heart Institute

Houston, Texas, 77030, United States
The University of Vermont Medical Center

Burlington, Vermont, 05401, United States
University of Colorado

Aurora, Colorado, 80045, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Pittsburgh Medical Center

Mechanicsburg, Pennsylvania, 17050, United States
University of Southern California

Los Angeles, California, 90033, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Evogliptin (also called DA-1229), a diabetes drug being tested for heart valve disease

What this could lead to

If it works, this could point toward a medication that slows or stops the worsening of aortic valve disease, potentially delaying the need for surgery.

What could go wrong

This is an early-to-mid-stage trial that is currently suspended, so results are uncertain. The drug may not slow valve calcification, and side effects are still being studied.

Conditions

The condition(s) this trial relates to.

aortic valve calcification

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CALCIFIC AORTIC VALVE DISEASE